Ranitidine Hydrochloride Injection IP 25mg/ml Manufacturers Suppliers - Third Party Manufacturing - Contract Manufacturer
Each ml Contains: Ranitidine Hydrochloride IP Equivalent to Ranitidine 25mg Preservative: Phenol IP 0.5%w/v Water for Injections IP
Ranitidine Hydrochloride Injection IP: at a concentration of 25mg/ml, is a medication used to treat conditions related to excess stomach acid production. It belongs to the H2 receptor antagonist class, thereby reducing acid secretion. This injection is commonly employed for the short-term management of ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome. By diminishing gastric acidity, it helps alleviate symptoms such as heartburn and promotes the healing of stomach ulcers. It is administered intravenously under medical supervision, providing rapid relief in acute situations where oral intake is challenging or ineffective.
Ranitidine Hydrochloride Injection IP, at 25mg/ml concentration, offers swift relief from conditions like ulcers, GERD, and hyperacidity. Administered intravenously, it provides a rapid onset of action, crucial in emergencies or when oral intake is impractical. By inhibiting stomach acid production through H2 receptor antagonism, the injection effectively alleviates symptoms such as heartburn and supports ulcer healing. Additionally, Ranitidine is known for its safety profile and can be an essential component of comprehensive medical strategies for gastrointestinal disorders. Its efficient acid-suppressing properties make it valuable in critical care settings, ensuring prompt and effective treatment.
Ranitidine Hydrochloride Injection IP at 25mg/ml is typically administered intravenously under medical supervision. The dosage depends on the specific condition being treated and the patient’s response. Healthcare professionals usually determine the appropriate dosage and infusion rate. The injection should be given slowly over a specific timeframe, as directed by the healthcare provider. It is crucial to follow the prescribed administration guidelines to achieve optimal therapeutic outcomes and minimize potential side effects. Patients should inform their healthcare provider about any existing medical conditions or medications to ensure safe and effective use of Ranitidine Hydrochloride Injection IP.
Ranitidine Hydrochloride Injection IP at 25mg/ml operates as an H2 receptor antagonist, hindering the action of histamine on stomach cells. By selectively blocking H2 receptors, it reduces the production of gastric acid, a key factor in digestive processes. This inhibitory effect on acid secretion is pivotal in treating conditions like ulcers and gastroesophageal reflux disease (GERD). The injection’s rapid onset and potency make it particularly effective in acute situations. By moderating acid levels, Ranitidine alleviates symptoms such as heartburn and aids in the healing of gastric ulcers, providing relief and contributing to the overall management of gastrointestinal disorders.
While using Ranitidine Hydrochloride Injection IP at 25mg/ml, precautions are essential. Patients with a history of hypersensitivity to ranitidine or related substances should avoid it. Caution is advised in individuals with impaired kidney function. Continuous monitoring of vital signs is crucial during administration. Interactions with other medications should be considered, especially those affected by changes in gastric pH. Patients should disclose their medical history, including liver or kidney issues, to the healthcare provider. As with any medication, adverse reactions should be promptly reported. Proper dosage and administration under healthcare supervision are vital to ensure safe and effective use of Ranitidine Hydrochloride Injection IP.
Ranitidine Hydrochloride Injection IP at 25mg/ml might cause side effects, including headache, dizziness, and gastrointestinal disturbances like nausea or constipation. Rarely, more serious reactions such as allergic reactions, liver dysfunction, or blood disorders might occur. Prolonged use might be associated with an increased risk of pneumonia and clostridium difficile-associated diarrhea. In extremely rare cases, it has been linked to adverse cardiac events. Patients experiencing severe or persistent side effects should seek medical attention. It is crucial to discuss potential risks and benefits with a healthcare provider to ensure appropriate monitoring and management of any adverse reactions.